Etaracizumab, formerly known as MEDI523 and subsequently LM609, represents a unique strategy in antibody-mediated therapy. This monoclonal immunoglobulin is built to selectively neutralize the activity of C1q, a critical component of the cascade involved in inflammation . Data have focused on it